Items where authors include "Banerji, U."

Article

Kristeleit, R. orcid.org/0000-0003-3825-1326, Plummer, R., Jones, R. et al. (11 more authors) (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer, 129. pp. 38-45. ISSN 0007-0920

Dillon, M.T., Boylan, Z., Smith, D. et al. (10 more authors) (2018) PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clinical and Translational Radiation Oncology, 12. pp. 16-20. ISSN 2405-6308

Conference or Workshop Item

Lahu, G., Banerji, U., Tap, W.C. et al. (15 more authors) (2025) Abstract CT151: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates. In: AACR Annual Meeting 2025, 25-30 Apr 2025, Chicago, Illinois.

Proceedings Paper

Banerji, U., Cook, N., Anthoney, A. et al. (11 more authors) (2024) Abstract CT188: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. In: Cancer Research. AACR Annual Meeting 2024, 05-10 Apr 2024, San Diego, USA. American Association for Cancer Research , ct188-ct188.